Loading
Extracellular Vesicles in Disease · Journal article
Journal of Biological Engineering · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study of aptamer-functionalized exosomes co-delivering a miR-934 inhibitor and gemcitabine in pancreatic cancer cell lines and xenograft models. The platform showed enhanced tumor targeting and suppressed tumor growth compared to free drug and non-functionalized exosomes; however, no quantified effect sizes, statistical significance values, or human data are provided, and the work remains at the discovery stage.
Preclinical in vitro and in vivo study. Pancreatic cancer cell lines and subcutaneous xenograft tumor models in mice. Intervention: AS1411-functionalized exosomes co-delivering miR-934 inhibitor and gemcitabine. Compared with: Free gemcitabine and non-functionalized exosomes.
miR-934 inhibitor plus gemcitabine co-delivered by AS1411-functionalized exosomes suppressed tumor growth in vivo compared with free drug treatment and non-functionalized exosomes PRUNE2 overexpression reversed miR-934-induced malignant phenotypes and gemcitabine resistance in vitro Functionalized exosomes demonstrated high encapsulation efficiency and enhanced cellular uptake and tumor-targeting capability
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is exploratory and does not yet inform clinical practice. Translation to human pancreatic cancer would require phase 1 safety and dose-escalation studies, followed by efficacy trials.
Preclinical in vitro and in vivo work demonstrating proof-of-concept for a novel engineered exosome delivery platform; lacks human clinical data, phase trials, or controlled comparator arms with reported effect sizes and statistical significance.
As stated by the source record.
This work is exploratory and does not yet inform clinical practice. Translation to human pancreatic cancer would require phase 1 safety and dose-escalation studies, followed by efficacy trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Pancreatic cancer remains a malignancy with limited treatment efficacy and high resistance to chemotherapy. miR-934 was identified as an oncogenic miRNA significantly upregulated in pancreatic cancer, promoting tumor progression, epithelial-mesenchymal transition (EMT), and chemoresistance by targeting the tumor suppressor PRUNE2. Inhibition of miR-934 sensitized cancer cells to Gemcitabine (GEM)-induced apoptosis, highlighting its therapeutic potential. To enhance delivery efficiency, AS1411 (oligonucleotide aptamer of nucleolin)-functionalized exosomes were engineered to co-deliver miR-934 inhibitor and GEM. The functionalized exosomes demonstrated high encapsulation efficiency, enhanced cellular uptake and tumor-targeting capability, and improved suppression of malignant phenotypes. This platform not only suppressed cell migration, invasion, and EMT but also enhanced GEM-induced apoptosis by restoring PRUNE2 expression and activating pro-apoptotic pathways. Furthermore, PRUNE2 overexpression reversed the malignant phenotypes and gemcitabine resistance induced by miR-934, further confirming the critical role of the miR-934/PRUNE2 axis in pancreatic cancer progression. In vivo, AS1411-functionalized engineered exosomes co-delivering miR-934 inhibitor and gemcitabine exhibited enhanced tumor accumulation and significantly suppressed tumor growth compared with free drug treatment and non-functionalized exosomes. These findings underscore the potential of aptamer-functionalized exosomes as a targeted therapeutic strategy for pancreatic cancer by integrating miRNA modulation and chemotherapeutic delivery.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.